文献速递心脑血管急症重症综合管理与镇静镇痛

吸入氙气对院外心脏骤停后脑灰质结构改变的神经保护作用:形态学分析——随机Xe-Hypotheca试验的子研究

Neuroprotective Effects of Inhaled Xenon Gas on Brain Structural Gray Matter Changes After Out-of-Hospital Cardiac Arrest Evaluated by Morphometric Analysis: A Substudy of the Randomized Xe-Hypotheca Trial.
PubMed 文献 · Neurocrit Care · 2024-07-09
一句话结论Xe-Hypotheca子研究显示,院外心脏骤停后昏迷幸存者中,吸入氙气联合目标温度管理(33℃)较单纯低温治疗更好地保留了脑灰质体积。

该研究为随机Xe-Hypotheca试验的预设次要分析,纳入110例院外心脏骤停后昏迷幸存者,随机接受吸入氙气联合目标温度管理(33℃,24小时,n=55)或单纯目标温度管理(n=55)。66例完成两次脑MRI,经影像学排除后,最终对照组21例、氙气组24例的两次扫描符合质控标准并纳入分析。基于体素的形态学分析显示,对照组第二次扫描较第一次在多个灰质簇出现显著体积下降;组间比较中,右侧杏仁核/内嗅皮层(p=0.025)、左侧杏仁核(p=0.043)、左侧颞中回(p=0.042)、左侧颞下回(p=0.008)、左侧海马旁回(p=0.042)、左侧颞极(p=0.042)及左侧小脑皮层(p=0.005)的灰质体积减少在对照组更显著,其余灰质区域组间无显著差异。作者结论认为,吸入氙气联合目标温度管理较单纯低温治疗更好地保留了灰质。

要点

  • 院外心脏骤停后昏迷幸存者中,吸入氙气联合目标温度管理(33℃)24小时较单纯目标温度管理在多个灰质区域体积保留更好。
  • 组间比较显示右侧杏仁核/内嗅皮层(p=0.025)、左侧颞下回(p=0.008)、左侧小脑皮层(p=0.005)等区域灰质体积减少在对照组更显著。
  • 其余灰质区域组间无显著变化。
  • 最终影像分析仅纳入对照组21例、氙气组24例完成两次合格MRI扫描的患者。

适用人群与场景

  • 院外心脏骤停后昏迷幸存者,随机接受吸入氙气联合目标温度管理(33℃)24小时或单纯目标温度管理。

处置流程与药物剂量

  • 吸入氙气联合目标温度管理(33℃)持续24小时;对照组仅接受目标温度管理(33℃)。

研究设计与关键结果

  • 研究类型:随机Xe-Hypotheca试验的预设次要分析;样本量:随机110例(氙气组n=55,对照组n=55),完成两次MRI 66例,最终分析对照组21例、氙气组24例。
  • 干预与对照:吸入氙气联合目标温度管理(33℃)24小时 vs 单纯目标温度管理。
  • 主要终点结果:基于体素的形态学分析显示,对照组第二次扫描较第一次在多个灰质簇体积显著下降;组间比较中,右侧杏仁核/内嗅皮层(p=0.025)、左侧杏仁核(p=0.043)、左侧颞中回(p=0.042)、左侧颞下回(p=0.008)、左侧海马旁回(p=0.042)、左侧颞极(p=0.042)、左侧小脑皮层(p=0.005)的灰质体积减少在对照组更显著。
  • 其余灰质区域组间无显著变化。

证据类型、等级与局限

  • 证据类型:随机对照试验(Xe-Hypotheca)的子研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在院外心脏骤停后昏迷幸存者中,吸入氙气联合目标温度管理较单纯低温治疗更好地保留了灰质。

指南或共识出处

  • Xe-Hypotheca试验(ClinicalTrials.gov: NCT00879892)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We have earlier reported that inhaled xenon combined with hypothermia attenuates brain white matter injury in comatose survivors of out-of-hospital cardiac arrest (OHCA). A predefined secondary objective was to assess the effect of inhaled xenon on the structural changes in gray matter in comatose survivors after OHCA.

METHODS: Patients were randomly assigned to receive either inhaled xenon combined with target temperature management (33 °C) for 24 h (n = 55, xenon group) or target temperature management alone (n = 55, control group). A change of brain gray matter volume was assessed with a voxel-based morphometry evaluation of high-resolution structural brain magnetic resonance imaging (MRI) data with Statistical Parametric Mapping. Patients were scheduled to undergo the first MRI between 36 and 52 h and a second MRI 10 days after OHCA.

RESULTS: Of the 110 randomly assigned patients in the Xe-Hypotheca trial, 66 patients completed both MRI scans. After all imaging-based exclusions, 21 patients in the control group and 24 patients in the xenon group had both scan 1 and scan 2 available for analyses with scans that fulfilled the quality criteria. Compared with the xenon group, the control group had a significant decrease in brain gray matter volume in several clusters in the second scan compared with the first. In a between-group analysis, significant reductions were found in the right amygdala/entorhinal cortex (p = 0.025), left amygdala (p = 0.043), left middle temporal gyrus (p = 0.042), left inferior temporal gyrus (p = 0.008), left parahippocampal gyrus (p = 0.042), left temporal pole (p = 0.042), and left cerebellar cortex (p = 0.005). In the remaining gray matter areas, there were no significant changes between the groups.

CONCLUSIONS: In comatose survivors of OHCA, inhaled xenon combined with targeted temperature management preserved gray matter better than hypothermia alone.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT00879892.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Hollmén C, Parkkola R, Vorobyev V, et al. Neuroprotective Effects of Inhaled Xenon Gas on Brain Structural Gray Matter Changes After Out-of-Hospital Cardiac Arrest Evaluated by Morphometric Analysis: A Substudy of the Randomized Xe-Hypotheca Trial. Neurocrit Care. 2024. PMID: 38982000. doi:10.1007/s12028-024-02053-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。